Burkholderia cenocepacia and Burkholderia multivorans are opportunistic drug-resistant pathogens that account for the majority of Burkholderia cepacia complex infections in cystic fibrosis patients and also infect other immunocompromised individuals. While they share similar genetic compositions, B. cenocepacia and B. multivorans exhibit important differences in pathogenesis. We have developed reconciled genome-scale metabolic network reconstructions of B. cenocepacia J2315 and B. multivorans ATCC 17616 in parallel (designated iPY1537 and iJB1411, respectively) to compare metabolic abilities and contextualize genetic differences between species. The reconstructions capture the metabolic functions of the two species and give insight into similarities and differences in their virulence and growth capabilities. The two reconstructions have 1,437 reactions in common, and iPY1537 and iJB1411 have 67 and 36 metabolic reactions unique to each, respectively. After curating the extensive reservoir of metabolic genes in Burkholderia, we identified 6 genes essential to growth that are unique to iPY1513 and 13 genes uniquely essential to iJB1411. The reconstructions were refined and validated by comparing in silico growth predictions to in vitro growth capabilities of B. cenocepacia J2315, B. cenocepacia K56-2, and B. multivorans ATCC 17616 on 104 carbon sources. Overall, we identified functional pathways that indicate B. cenocepacia can produce a wider array of virulence factors compared to B. multivorans, which supports the clinical observation that B. cenocepacia is more virulent than B. multivorans. The reconciled reconstructions provide a framework for generating and testing hypotheses on the metabolic and virulence capabilities of these two related emerging pathogens.
Multidrug-resistant pathogens are a severe health concern and can cause chronic infections in a variety of patient populations with limited recourse for treatment. Here, we investigate two multidrug-resistant species, Burkholderia cenocepacia and Burkholderia multivorans, of the Burkholderia cepacia complex (BCC) which are considered dangerous and difficult to treat in patients with cystic fibrosis (CF), chronic granulomatous disease, or compromised immune systems (1). With larger genomes (8.06 Mbp and 7.01 Mbp, respectively) than many other multidrug-resistant pathogens, they also contain an expanded reservoir of genes that may assist their ability to avoid clinical eradication (2-4). Because they are nosocomial, transmissible between patients, and also routinely acquired (and reacquired) from the environment, B. cenocepacia and B. multivorans are the two BCC species most commonly isolated from the sputum of CF patients (5-8). In patients with CF, pulmonary infection with BCC can contribute to the rapid deterioration of lung function known as cepacia syndrome, a necrotizing pneumonia that can lead to bacteremia, septicemia, and increased mortality (9, 10). A combination of high antibiotic resistance and decreased immune function in patients makes B. cen...